PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 58 | 3 | 345-347
Article title

Antibiotic therapy and fat digestion and absorption in cystic fibrosis

Content
Title variants
Languages of publication
EN
Abstracts
EN
Antibiotic therapy in the cystic fibrosis (CF) mouse model has been shown to result in reduced bacterial load of the intestine and significant body mass gain. The effect was suggested to be linked to the improvement of intestinal digestion and absorption. Therefore, we aimed to assess the influence of routinely applied antibiotic therapy in CF patients on fat assimilation. Twenty-four CF patients aged 6 to 30 years entered the study. Inclusion criteria comprised confirmed exocrine pancreatic insufficiency and bronchopulmonary exacerbation demanding antibiotic therapy. Exclusion criteria comprised: antibiotic therapy six weeks prior to the test, liver cirrhosis, diabetes mellitus, oxygen dependency, the use of systemic corticosteroids. In all enrolled CF subjects, 13C-labelled mixed triglyceride breath test (13C MTG-BT) was performed to assess lipid digestion and absorption, before and after antibiotic therapy. Sixteen subjects were treated intravenously with ceftazidime and amikacin, eight patients orally with ciprofloxacin. Cumulative percentage dose recovery (CPDR) was considered to reflect digestion and absorption of lipids. The values are expressed as means (medians). The values of CPDR before and after antibiotic therapy did not differ in the whole studied group [4.6(3.3) % vs. 5.7(5.3) %, p = 0.100] as well as in the subgroup receiving them intravenously [4.6(3.2) % vs. 5.7(5.3) %, p = 0.327] or in that with oral drug administration [4.6(3.4) % vs. 5.7(5.4) %, p = 0.167]. In conclusion, antibiotic therapy applied routinely in the course of pulmonary exacerbation in CF patients does not seem to result in an improvement of fat digestion and absorption.
Publisher

Year
Volume
58
Issue
3
Pages
345-347
Physical description
Dates
published
2011
received
2010-12-10
revised
2011-05-13
accepted
2011-07-05
(unknown)
2011-07-07
Contributors
  • 1st Chair of Pediatrics, Department of Pediatric Gastroenterology & Metabolism, Poznań University of Medical Sciences, Poznań, Poland
  • Department of Bronchology & Cystic Fibrosis, National Institute for Tuberculosis & Lung Diseases, Pediatric Branch, Rabka, Poland
  • Department of Pediatric Gastroenterology, Hepatology & Immunology, Child Memorial Health Institute, Warszawa, Poland
  • 1st Clinic of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warszawa, Poland
  • Department of Respiratory Medicine, Poznań University of Medical Sciences, Poznań, Poland
  • Department of Pediatric Otorhinolaryngology, Poznań University of Medical Sciences, Poznań, Poland
author
  • Department of Pediatric Gastroenterology, Hepatology & Immunology, Child Memorial Health Institute, Warszawa, Poland
  • 1st Chair of Pediatrics, Department of Pediatric Gastroenterology & Metabolism, Poznań University of Medical Sciences, Poznań, Poland
References
  • Béghin L, Gottrand F, Michaud L, Loeuille GA, Wizla-Derambure N, Sardet A, Guimber D, Deschildre A, Turck D (2003) Impact of intravenous antibiotic therapy on total daily energy expenditure and physical activity in cystic fibrosis children with Pseudomonas aeruginosa pulmonary exacerbation. Pediatr Res 54: 756-761.
  • Castro M, Diamanti A, Gambarara M, Bella S, Lucidi V, Papadatou B, Ferretti F, Rosati P, Rupi E (2002) Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations. Clin Nutr 21: 141-144.
  • Hankard R, Munck A, Navarro J (2002) Nutrition and growth in cystic fibrosis. Horm Res 58 (Suppl 1): 16-20.
  • Muhlebach MS, Stewart PW, Leigh MW, Noah TL (1999) Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160: 186-191.
  • Norkina O, Burnett DG, De Lisle RC (2004a) Bacterial overgrowth in cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040-6049.
  • Norkina O, Kaur S, Ziemer D, De Lisle RC (2004b) Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 286: G1032-G1041.
  • Reilly JJ, Evans TJ, Wilkinson J, Paton JY (1999) Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis. Arch Dis Child 81: 120-124.
  • Vic P, Ategbo S, Gottrand F, Launay V, Loeuille GA, Elian JC, Druon D, Farriaux JP, Turck D (1997) Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Arch Dis Child 76: 437-440.
  • Walkowiak J (2004) Assessment of maldigestion in cystic fibrosis. J Pediatr 145: 285-287.
  • Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA (2005) Indirect pancreatic function tests in children. J Pediatr Gastroenterol Nutr 40: 107-114.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv58p345kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.